Le Duy Cao Phuong, Bui Hoa The, Vu Yen Thi Hai, Vo Quan Duy
Departmentof Cardiovascular Intervention, Nguyen Tri Phuong Hospital, Ho Chi Minh city, 700000, Vietnam.
Faculty of Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, 700000, Vietnam.
Regen Med. 2024 Sep-Oct;19(9-10):497-509. doi: 10.1080/17460751.2024.2393558. Epub 2024 Sep 12.
Heart failure (HF) causes over 266,400 deaths annually. Despite treatment advancements, HF mortality remains high. Induced pluripotent stem cells (iPSCs) offer promising new options. This review assesses iPSC-based treatments for HF. the review included studies from PubMed, ScienceDirect and Web of Science. Analysis of 25 studies with 553 animals showed a baseline ejection fraction (EF) of 39.2 ± 8.9%. iPSC treatment significantly improved EF (MD = 8.6, < 0.001) and fractional shortening (MD = 6.38, < 0.001), and reduced ventricular remodeling without increasing arrhythmia risk. iPSC-based therapy improves heart function and reduces ventricular volumes in HF animal models, aligning with promising early clinical trial outcomes.
心力衰竭（HF）每年导致超过266,400人死亡。尽管治疗取得了进展，但HF死亡率仍然很高。诱导多能干细胞（iPSC）提供了有前景的新选择。本综述评估了基于iPSC的HF治疗方法。该综述纳入了来自PubMed、ScienceDirect和科学网的研究。对25项涉及553只动物的研究分析显示，基线射血分数（EF）为39.2±8.9%。iPSC治疗显著改善了EF（MD = 8.6，<0.001）和缩短分数（MD = 6.38，<0.001），并减少了心室重构，且未增加心律失常风险。基于iPSC的疗法可改善HF动物模型的心脏功能并减少心室容积，这与早期临床试验的良好结果相符。
